American Medical Association, Council on Scientific Affairs. Medical and non-medical uses of anabolic-androgenic steroids. J. Amer. Med. Assoc. 264: 2923-2927, 1990.
Bahrke, ., . Yesalosk, and . Wright. Psychological and behavioural effects of endogenous testosterone levels and anabolic-androgenic steroids among males: a review. Sports Med. 10: 303-337, 1990.
Buckley, ., . Yasalis, . Friedl, . Anderson, . Streit, and . Wright. Estimated prevalance of anabolic steroid use among male high school seniors. J. Amer. Med. Assoc. 260: 3441-3445, 1988.
Rogozkin, V. Metabolism of Anabolic Androgenic Steroids. Leningrad: Nauka, 1988.
United States Olympic Committee. USOC Drug Education Handbook. Colorado Springs: USOC, 1989.
Assessment of Aggressive Behavior and Plasma Testosterone in a Young Criminal PopulationLeo E. Kreuz, MD, MAJ, MCand Robert M. Rose, MD, June 23, 1971. Revision received December 1, 1971. 1972 American Psychosomatic Society
BEHRE, ., K. ABSHAGEN, M. OETTEL, D. HUBLER AND E. NIESCHLAG. Intramuscular injection of testosterone undecanoate for the treatment of male hypogonadism: phase I studies. Eur J Endocrinol 140:414 ***8211; 419. 1999
Corticosteroid myopathy presents as weakness and wasting of the proximal limb and girdle muscles and is generally reversible following cessation of therapy.
Corticosteroids inhibit intestinal calcium absorption and increase urinary calcium excretion leading to bone resorption and bone loss. Bone loss of 3% over one year has been demonstrated with prednisolone 10 mg per day. Postmenopausal females are particularly at risk for loss of bone density. Sixteen percent of elderly patients treated with corticosteroids for 5 years may experience vertebral compression fractures. One author reported measurable bone loss over two years in women on concomitant therapy with prednisolone mg per day and tamoxifen. [ Ref ]